Drugs Directory & Medical Information

Empowering Healthcare Decisions
Right at the point of Care

Powered by AI - Try searching for:

Multi-Specialty Diabetic Peripheral Neuropathy Peripheral neuropathy Neuropathy Diabetes Mellitus Diabetes Mellitus Complications

When elderly patients complain of paresthesia or numbness, the initial response from the patients themselves, their families, and sometimes even physicians, would be to consider the symptoms as part of the aging process. Yet what feels like a natural part of aging could, in fact, be an early sign of a treatable neurological condition: one that, if left unaddressed, carries serious consequences for health, function, and quality of life. This was the central message at the Neurobion Neuropathy Awareness Week celebration, held on 3 June 2026 at Luxent Hotel, Quezon City. Presented by P&G Health, this event brought healthcare practitioners together for an evening of scientific discussion and expert insights. It also saw the formal launch of the “Caring for the Hands That Care” campaign, which challenges the long-held but potentially harmful assumption that symptoms of nerve damage in elderly patients are simply an inevitable consequence of growing old.

20 Sep 2026

Cardiology Explore the evidence for carvedilol in heart failure with reduced ejection fraction (HFrEF), with a focus on its demonstrated benefits in reducing mortality, hospitalization, and disease-related morbidity.

Heart failure with reduced ejection fraction (HFrEF) remains a major cause of morbidity and mortality, with recurrent hospitalizations often marking a challenging phase in the patient journey. For patients, being discharged is not the end of their treatment journey. While discharge from the hospital represents an important milestone, long-term management is essential to reduce the risk of clinical deterioration and improve survival.1 Carvedilol, a beta-blocker recommended as part of guideline-directed treatment for heart failure. Guideline-directed medical therapy (GDMT) refers to the combination of evidence-based medicine recommended to improve outcomes for patients with HFrEF. Current treatment generally centers on four key pillars: an angiotensin receptor–neprilysin inhibitor (ARNi), a mineralocorticoid receptor antagonist (MRA), and a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and a beta-blocker such as carvedilol. Together, these therapies work through different pathways to help reduce symptoms, slow disease progression, lower the risk of hospitalization, and improve survival.

14 Sep 2026

$Explore the evidence for carvedilol in heart failure with reduced ejection fraction (HFrEF), with a focus on its demonstrated benefits in reducing mortality, hospitalization, and disease-related morbidity.$

Multi-Specialty Ketoanalogues + essential amino acids in chronic kidney disease: A nutritional-pharmacologic strategy to slow disease progression in CKD

Chronic kidney disease (CKD), particularly diabetic kidney disease (DKD),is a major global clinical burden. Nutritional therapy is central in conservative (non‑dialysis) CKD management.

25 Aug 2026

Ketoanalogues + essential amino acids in
chronic kidney disease: A nutritional-pharmacologic
strategy to slow disease progression in CKD

Endocrinology Product Highlight - Sitagliptin (SITAZUCA®)

Film-coated tablet 50 mg and 100 mg

24 Aug 2026

Product Highlight - Sitagliptin (SITAZUCA®)

What is MIMS

For over 60 years, MIMS has served as Asia-Pacific region's leading clinical drug dictionary and medical decision-support platform, trusted by over 2.1 million healthcare professionals. MIMS delivers independent, evidence-based prescription drug monographs, multi-drug interaction checks, and localized regulatory guidelines designed to support confident decision-making at the point of care.